Patents by Inventor Xiangbing QI

Xiangbing QI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport
    Patent number: 11701369
    Abstract: The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile acid or salt thereof, and a second HBV or HDV medicament.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: July 18, 2023
    Assignee: Huahui Health Ltd.
    Inventors: Wenhui Li, Xiangbing Qi, Huan Yan, Yang Liu, Zhiqiang Wang, Bo Peng, Lei Zhang
  • ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK
    Publication number: 20210338706
    Abstract: The present invention provides a kind of nucleoside analogue compounds, and a composition comprising the compound and pentostatin, their use for modulating circadian rhythm, preferably, for shifting circadian phase, and methods for modulating circadian rhythm, preferably, for shifting circadian phase via the compound or the composition.
    Type: Application
    Filed: January 20, 2018
    Publication date: November 4, 2021
    Inventors: Erquan ZHANG, Xiangbing QI, Dapeng JU, Zhiqiang WANG, Qingcui WU, Haijiao ZHAO, Long MEI
  • Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof
    Patent number: 10167258
    Abstract: The present disclosure relates to the identification of PDK inhibitors and their use in the treatment of diseases such as diabetes, cardiovascular disease and cancer. The invention relates to the development of robust PDK inhibitors that can be used to improve glucose metabolism and correct metabolic dysfunction in vivo. Based on the unique structural features present in the ATP-binding pocket of PDK2, a single functional-group change was made in a known Hsp90 inhibitor that binds to the corresponding pocket of the latter protein from the GHKL family. This approach efficiently converted the Hsp90 inhibitor to a highly specific inhibitor for all PDK isoforms. These final PDK inhibitors of this series robustly augments PDC activity with reduced phosphorylation in tissues.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 1, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David T. Chuang, Shih-Chia Tso, Xiangbing Qi, Wen-Jun Gui, Cheng-Yang Wu, Jacinta L. Chuang, Uttam K. Tambar, R. Max Wynn
  • POLYMERIC BILE ACID DERIVATIVES INHIBIT HEPATITIS B AND D VIRUS AND NTCP TRANSPORT
    Publication number: 20170266206
    Abstract: The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile acid or salt thereof, and a second HBV or HDV medicament.
    Type: Application
    Filed: September 28, 2015
    Publication date: September 21, 2017
    Applicant: Huahui Health Ltd.
    Inventors: Wenhui Li, Xiangbing Qi, Huan Yan, Yang Liu, Zhiqiang Wang, Bo Peng, Lei Zhang
  • INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF
    Publication number: 20170001958
    Abstract: The present disclosure relates to the identification of PDK inhibitors and their use in the treatment of diseases such as diabetes, cardiovascular disease and cancer. The invention relates to the development of robust PDK inhibitors that can be used to improve glucose metabolism and correct metabolic dysfunction in vivo. Based on the unique structural features present in the ATP-binding pocket of PDK2, a single functional-group change was made in a known Hsp90 inhibitor that binds to the corresponding pocket of the latter protein from the GHKL family. This approach efficiently converted the Hsp90 inhibitor to a highly specific inhibitor for all PDK isoforms. These final PDK inhibitors of this series robustly augments PDC activity with reduced phosphorylation in tissues.
    Type: Application
    Filed: December 12, 2014
    Publication date: January 5, 2017
    Applicant: The Board of Regents of the University of Texas System
    Inventors: David T. CHUANG, Shih-Chia TSO, Xiangbing QI, Wen-Jun GUI, Cheng-Yang WU, Jacinta L. CHUANG, Uttam K. TAMBAR, R. Max WYNN